Diaz Discusses the FDA Approval of Pembrolizumab for MSI-H Solid Tumors

July 10, 2017
Luis A. Diaz Jr, MD

Luis A. Diaz Jr, MD, head, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, discusses the recent FDA approval of pembrolizumab (Keytruda) for microsatellite instability-high (MSI-H) colorectal cancer and other tumor types.